Ferris and colleagues published a subgroup analysis in their trial according PD-1 and HPV status in which preliminary evidence suggested that patients with a tumor PD-L1 expression of 1% or more or p16 positive tumors may have greater effect from ICB, although the survival rate at two years was similar (12). The gene discussed is CD274; the disease is neoplasm.